The Joint Corp. Signs Binding Agreement to Sell 31 Corporate Clinics in Arizona and New Mexico and to Acquire Regional Developer Rights in the Northwest Region and Refranchises Five Corporate Clinics in the Kansas City Region, Tracking to Become Largest Pure Play Chiropractic Care Franchise System
Viking Therapeutics Announces Initiation of Phase 3 Obesity Clinical Program with GLP-1/GIP Agonist VK2735
Indaptus Therapeutics Notification (INDP)
Amicus Therapeutics Announces Approval ofPombiliti® (cipaglucosidase alfa) +Opfolda® (miglustat) in Japan
Gilead - Gilead Sciences and Kymera Therapeutics Enter Into Exclusive Option and License Agreement to Develop Novel Oral Molecular Glue CDK2 Degraders
CalciMedica Announces Publication in the American Journal of Nephrology Discussing Design and Rationale of Phase 2 KOURAGE Trial ofAuxora™ in AKI with Respiratory Failure
New Form 8-K - STAAR SURGICAL CO Filed: 2025-06-25 AccNo: 0000950170-25-089733 Size: 202 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Precision BioSciences Receives FDA Rare Pediatric Disease Designation for PBGENE-DMD for the Treatment of Duchenne Muscular Dystrophy
Iterum Therapeutics Announces Publication of REASSURE Trial in NEJM Evidence
Glaukos - Glaukos to Celebrate 10th Anniversary of IPO Listing with NYSE Closing Bell
Q32 Bio Appoints Adrien Sipos, M.D., Ph.D., as Interim Chief Medical Officer
Glaukos to Celebrate 10th Anniversary of IPO Listing with NYSE Closing Bell
Indaptus Therapeutics Announces Reverse Stock Split